Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- XLO
- Price
- 0.62
- Stock movement up
- +0.02 (3.40%)
- Company name
- Xilio Development Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 32.41M
- Ent value
- 70.44M
- Price/Sales
- 1.02
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -51.39%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
XLO does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.02 |
| Price to Book | - |
| EV to Sales | 2.21 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 52.50M |
| EPS (TTM) | -0.41 |
| FCF per share (TTM) | -0.12 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 31.80M |
| Gross profit (TTM) | 16.13M |
| Operating income (TTM) | -43.77M |
| Net income (TTM) | -58.49M |
| EPS (TTM) | -0.41 |
| EPS (1y forward) | -0.18 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 50.73% |
| Operating margin (TTM) | -137.64% |
| Profit margin (TTM) | -183.90% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 103.76M |
| Net receivables | 0.00 |
| Total current assets | 124.09M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 16.26M |
| Total assets | 133.69M |
| Accounts payable | 2.30M |
| Short/Current long term debt | 7.26M |
| Total current liabilities | 56.40M |
| Total liabilities | 141.79M |
| Shareholder's equity | -8.10M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -17.15M |
| Capital expenditures (TTM) | 429.00K |
| Free cash flow (TTM) | -17.58M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -43.75% |
| Return on Invested Capital | 861.15% |
| Cash Return on Invested Capital | 258.83% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.60 |
| Daily high | 0.63 |
| Daily low | 0.57 |
| Daily Volume | 1.61M |
| All-time high | 25.11 |
| 1y analyst estimate | 2.00 |
| Beta | -0.04 |
| EPS (TTM) | -0.41 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 4 Mar 2026 |
Downside potential
Loading...
Downside potential data
| XLO | S&P500 | |
| Current price drop from All-time high | -97.54% | -0.89% |
| Highest price drop | -97.62% | -19.00% |
| Date of highest drop | 21 Jan 2026 | 8 Apr 2025 |
| Avg drop from high | -96.76% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
32.41M
Marketcap category
Small-cap
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Employees
64
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page